Abstract 1205TiP
Background
Extrapulmonary neuroendocrine carcinoma has a poor prognosis with a median survival of about 1 year. The current standard first-line treatment for extrapulmonary neuroendocrine carcinoma is etoposide combined with cisplatin (EP) or etoposide combined with carboplatin (EC). Camrelizumab (anti-PD-1 antibody) and apatinib (VEGFR2-TKI) have shown definite antitumor effects in a variety of solid tumors. The aim of this study is to evaluate the efficacy and safety of camrelizumab combined with EP/EC chemotherapy, followed by camrelizumab plus apatinib as first-line treatment for advanced or metastatic extrapulmonary neuroendocrine carcinoma.
Trial design
This prospective, single-arm, multicenter study plans to enroll 30 patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma who have not been systematically treated. Enrolled patients will receive 4-6 cycles of EP (etoposide 100mg/m2 d1-3 iv+ cisplatin 25mg/m2 d1-3 iv, repeated every 21 days) or EC (etoposide 100mg/m2 d1-3 iv+ carboplatin AUC=5 d1 iv, repeated every 21 days) in combination with camrelizumab (200mg iv d1, repeated every 21 days). Patients with remission or stable disease will receive camrelizumab (200mg, d1, iv, repeated every 21 days) plus apatinib (250mg orally, once daily) as maintainance therapy until disease progression or unacceptable toxicity. Camrelizumab will be administered for a total of 2 years, and patients with stable or remission disease will continue apatinib treatment until disease progression. The primary endpoint of this study is objective response rate (ORR), while secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety.
Clinical trial identification
NCT05142865.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14